<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24927">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01736514</url>
  </required_header>
  <id_info>
    <org_study_id>TMXALL-1001-TW</org_study_id>
    <nct_id>NCT01736514</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout</brief_title>
  <official_title>A Randomized, Open Label, Multicenter, Allopurinol- Controlled Study to Assess the Safety and Efficacy of Oral Febuxostat in Patients With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Taiwan, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open label, randomized, allopurinol-controlled, parallel-design
      study. Approximately 120 subjects will be randomly assigned in 1:1 ratio to receive
      febuxostat, or allopurinol for subjects with gout.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of subjects whose serum urate level decreases to &lt; 6.0 mg/dL</measure>
    <time_frame>week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent reduction in serum urate levels</measure>
    <time_frame>Baseline and at week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events, physical exam. and vital signs, tabo-tests and 12-lead ECG</measure>
    <time_frame>Baseline and at week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>febuxostat group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>allopurinol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>febuxostat</intervention_name>
    <description>oral</description>
    <arm_group_label>febuxostat group</arm_group_label>
    <other_name>Adenuric, Uloric, Feburic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>oral</description>
    <arm_group_label>allopurinol group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will also have a history or presence of gout as defined by the American
             College of Rheumatology (ACR) criteria

          -  Subject has serum urate level &gt;= 8.0 mg/dL at the screening Visit

        Exclusion Criteria:

          -  Female subject who is breast-feeding or pregnant

          -  Subject has a history of xanthinuria

          -  Subject who is intolerant of allopurinol, ie hypersensitivity, Steven-Johnson
             syndrome/topic epidermal necrolysis

          -  Subject who takes allopurinol &gt; 300 mg/day and with serum urate level &gt; 8mg/dL

          -  Subject who is HLA B*5801 positive

          -  Subject who is receiving thiazide diuretic therapy

          -  Subject who has secondary hyperuricemia

          -  Subject who requires concurrent therapy with any systemic or topical medications,
             prescribed or non-prescribed, containing aspirin or other salicylates (low doses of
             aspirin will be allowed(ie. =&lt; 325mg/day)

          -  Subject who requires therapy with prednisone &gt; 10 mg/ day during the study

          -  Subject who has active liver disease or hepatic dysfunction, defined as both ALT and
             AST &gt; 1.5 times the upper limit of normal

          -  Subject who has serum creatinine &gt;= 1.5mg/dL

          -  Subject who has any another significant medical condition as defined by the
             investigator that would interfere with the treatment, safety or compliance with the
             protocol (eg. A clinically significant ECG result)

          -  Subject who has a history of cancer (other than basal cell carcinoma of the skin)
             within 5 years prior to the study, or has taken any systemic cancer chemotherapy
             within 5 years prior to the study

          -  Subject who has previously participated in a clinical study in which febuxostat was
             administered

          -  Subject who has participated in another investigational trial within the 30 days
             prior to the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Taiwan, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linkou</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 27, 2012</lastchanged_date>
  <firstreceived_date>November 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>xanthine oxidase inhibitor</keyword>
  <keyword>Uric acid lowering drug</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
